Validation of a predictive calculator for optimal glycemic control and time-in-tight-range following CGM sensor placement in type 1 diabetes and pancreatic diabetes: a prospective study
Year: 2025
Type: article
Study design: Observational Study
Abstract: BACKGROUND: Continuous glucose monitoring (CGM) has improved diabetes management, yet not all patients benefit equally. We previously developed a predictive calculator using clinical and socioeconomic variables to estimate the likelihood of achieving optimal control after CGM initiation. This study prospectively validated the calculator in a real-world cohort. METHODS: A single-center prospective study included 102 adults with type 1 or pancreatic diabetes using multiple daily insulin injections, followed for three months. Optimal control was defined as time in range (TIR, 70-180 mg/dL) > 70% and time below range (TBR, <70 mg/dL) < 4%. Model performance was assessed using ROC analysis and correlation tests. RESULTS: Of 102 participants, 85 completed follow-up (median age: 53.6 years; 48% women; median diabetes duration: 12.9 years; baseline HbA1c: 7.6%). Thirty-three (38.8%) achieved optimal control. The calculator showed moderate discrimination (AUC = 0.639) and significant correlations with TIR (p = 0.230, p = 0.023) and time in tight range (TITR, 70-140 mg/dL) (p = 0.271, p = 0.019). Overall accuracy was 61.9%, lower than in the original cohort. Smoking predicted non-completion (p = 0.038). CONCLUSIONS: The calculator shows moderate accuracy in predicting glycemic control and TITR after CGM initiation. CGM adherence remains a challenge, warranting further study in publicly funded healthcare settings.
Source: Endocrine
Authors: Fernando Sebastian-Valles, Juan Javier López-Hidalgo, Silvia Cañas Sierra, Victor Navas-Moreno, Jose Alfonso Arranz Martín, Miguel Antonio Sampedro-Núñez, Mónica Marazuela
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,090
Awards: Integrómicas en enfermedades tiroideas autoinmunes: miRNoma, transcriptoma y análisis de célula individual para caracterizar nuevas aproximaciones clínicas y vías de susceptibilidad en ETAI, G1683558661, G1834500361, G2903830096, Arquitectura molecular en enfermedades autoinmunes tiroideas mediante transcriptómica espacial, ACROMICS: medicina de precisión de futuro en el diagnóstico y tratamiento de la Acromegalia, G6031705226, G684616945
OpenAlex ID: W4413682532
